Abstract
Purpose
To compare two-year treatment outcomes of subthreshold micropulse (577 nm) laser and aflibercept for diabetic macular edema (DME).
Study design
Retrospective case–control study.
Methods
A total 164 eyes in 164 DME patients treated with either micropulse laser (86 eyes) or intravitreal aflibercept monotherapy (78 eyes) were recruited. Main outcome measures included at least five Early Treatment Diabetic Retinopathy Study (ETDRS) letters’ improvement from baseline at 6, 12 and 24 months.
Results
Rescue aflibercept was initiated in 24% of eyes in micropulse laser group. At 6-month visit the aflibercept group achieved a higher percentage of eyes with at least 5-letter visual acuity improvement than micropulse laser group (56% vs 38%, P = 0.044), however, this was not the case at 12-month (45% vs 49%, P = 0.584) and 24-month visits (49% vs 57%, P = 0.227). At 6-month visit the aflibercept group achieved a higher percentage of eyes with at least 10% improvement of central macular thickness (73% vs 49%, P = 0.005), but this was not the case at 12-month (73% vs 70%, P = 0.995) and 24-month visits (85% vs 84%, P = 0.872).
Conclusion
Aflibercept achieved faster and higher rates of anatomical and functional improvement than micropulse laser in DME patients. Long term efficacy of treatment did not result in significant differences between aflibercept monotherapy and micropulse laser in DME patients. Primary treatment of micropulse laser with deferred rescue aflibercept might be the treatment option without reducing the chance of visual improvement in DME eyes.
Similar content being viewed by others
References
Wallick CJ, Hansen RN, Campbell J, Kiss S, Kowalski JW, Sullivan SD. Comorbidity and health care resource use among commercially insured non-elderly patients with diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2015;46:744–51.
Bahrami B, Hong T, Gilles MT, Chang A. Anti-VEGF therapy for diabetic eye diseases. Asia Pac J Ophthalmol (Phila). 2017;6:535–45.
Ziemssen F, Wachtlin J, Kuehlewein L, Gamulescu MA, Bertelmann T, Feucht N, et al. Intravitreal ranibizumab therapy for diabetic macular edema in routine practice: two-year real-life data from a non-interventional Multicenter Study in Germany. Diabetes Ther. 2018;9:2271–89.
Kourlaba G, Relakis J, Mahon R, Kalogeropoulou M, Pantelopoulou G, Kousidou O, et al. Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema. Cost Eff Resour Alloc. 2016;14:7.
Mekjavic JP, Balciuniene VJ, Ceklic L, Ernest J, Jamrichova Z, Nagy ZZ, et al. The burden of macular diseases in central and eastern Europe-implications for healthcare systems. Value Health Reg Issues. 2019;19:1–6.
Fong DS, Luong TQ, Contreras R, Jimenez JJ, Custis PH, Patel V, et al. Treatment patterns and 2-year vision outcomes with bevacizumab in diabetic macular edema: an analysis from a large US Integrated Health Care System. Retina. 2018;38:1830–8.
Zas M, Cotic M, Wu A, Wu L. Macular laser photocoagulation in the management of diabetic macular edema: Still relevant in 2020? Taiwan J Ophthalmol. 2020;10:87–94.
Vujosevic S, Martini F, Longhin E, Convento E, Cavarzeran F, Midena E. Subthreshold micropulse yellow laser versus subthreshold micropulse infrared laser in center-involving diabetic macular edema: morphologic and functional safety. Retina. 2015;35:1594–603.
Scholz P, Altay L, Fauser S. A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther. 2017;34:1528–55.
Abouhussein MA, Gomaa AR. Aflibercept plus micropulse laser versus aflibercept monotherapy for diabetic macular edema: 1-year results of a randomized clinical trial. Int Ophthalmol. 2020;40:1147–54.
Kanar HS, Arsan A, Altun A, Aki SF, Hacisalihoglu A. Can subthreshold micropulse yellow laser treatment change the anti-vascular endothelial growth factor algorithm in diabetic macular edema? A randomized clinical trial. Indian J Ophthalmol. 2020;68:145–51.
Fazel F, Bagheri M, Golabchi K, Jahanbani AH. Comparison of subthreshold diode laser micropulse therapy versus conventional photocoagulation laser therapy as primary treatment of diabetic macular edema. J Curr Ophthalmol. 2016;28:206–11.
Chhablani J, Alshareef R, Kim DT, Narayanan R, Goud A, Mathai A. Comparison of different settings for yellow subthreshold laser treatment in diabetic macular edema. BMC Ophthalmol. 2018;18:168.
Inagaki K, Ohkoshi K, Ohde S, Deshpande GA, Ebihara N, Murakami A. Comparative efficacy of pure yellow (577-nm) and 810-nm subthreshold micropulse laser photocoagulation combined with yellow (561–577-nm) direct photocoagulation for diabetic macular edema. Jpn J Ophthalmol. 2015;59:21–8.
Akkaya S, Acikalin B, Dogan YE, Coban F. Subthreshold micropulse laser versus intravitreal anti-VEGF for diabetic macular edema patients with relatively better visual acuity. Int J Ophthalmol. 2020;13:1606–11.
Nicolo M, Musetti D, Traverso CE. Yellow micropulse laser in diabetic macular edema: a short-term pilot study. Eur J Ophthalmol. 2014;24:885–9.
Donati MC, Murro V, Mucciolo DP, Giorgio D, Cinotti G, Virgili G, et al. Subthreshold yellow micropulse laser for treatment of diabetic macular edema: comparison between fixed and variable treatment regimen. Eur J Ophthalmol. 2020. https://doi.org/10.1177/1120672120915169.
Vujosevic S, Bottega Casciano EM, Pilotto E, Convento E, Midena E. Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina. 2010;30:908–16.
Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol. 1999;127:688–93.
Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130:972–9.
Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123:2376–85.
Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25.
Blindbaek SL, Peto T, Grauslund J. How do we evaluate the role of focal/grid photocoagulation in the treatment of diabetic macular edema? Acta Ophthalmol. 2018. https://doi.org/10.1111/aos.13997.
Vujosevic S, Martini F, Convento E, Longhin E, Kotsafti O, Parrozzani R, et al. Subthreshold laser therapy for diabetic macular edema: metabolic and safety issues. Curr Med Chem. 2013;20:3267–71.
Gao X, Xing D. Molecular mechanisms of cell proliferation induced by low power laser irradiation. J Biomed Sci. 2009;16:4.
Midena E, Bini S, Martini F, Enrica C, Pilotto E, Micera A, et al. Changes of aqueous humor müller cells' biomarkers in human patients affected by diabetic macular edema after subthreshold micropulse laser treatment. Retina. 2020;40(1):126–34. https://doi.org/10.1097/IAE.0000000000002356.
Vujosevic S, Gatti V, Muraca A, Brambilla M, Villani E, Nucci P, et al. Optical coherence tomography angiography changes after subthreshold micropulse yellow laser in diabetic macular edema. Retina. 2020;40(2):312–21. https://doi.org/10.1097/IAE.0000000000002383.
Chen G, Tzekov R, Li W, Jiang F, Mao S, Tong Y. subthreshold micropulse diode laser versus conventional laser photocoagulation for diabetic macular edema: a meta-analysis of randomized controlled trials. Retina. 2016;36:2059–65.
Miller K, Fortun JA. Diabetic macular edema: current understanding, pharmacologic treatment options, and developing therapies. Asia Pac J Ophthalmol (Phila). 2018;7:28–35.
Ohkoshi K, Yamaguchi T. Subthreshold micropulse diode laser photocoagulation for diabetic macular edema in Japanese patients. Am J Ophthalmol. 2010;149:133–9.
Mansouri A, Sampat KM, Malik KJ, Steiner JN, Glaser BM. Efficacy of subthreshold micropulse laser in the treatment of diabetic macular edema is influenced by pre-treatment central foveal thickness. Eye (Lond). 2014;28:1418–24.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
F. H. P. Lai, None; R. P. S. Chan, None; A. C. H. Lai, None; S. Tsang, None; T. T. Y. Woo, None; R. F. Lam, None; C. Y. F. Yuen, None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Corresponding Author: Frank Hiu Ping Lai
About this article
Cite this article
Lai, F.H.P., Chan, R.P.S., Lai, A.C.H. et al. Comparison of two-year treatment outcomes between subthreshold micropulse (577 nm) laser and aflibercept for diabetic macular edema. Jpn J Ophthalmol 65, 680–688 (2021). https://doi.org/10.1007/s10384-021-00846-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-021-00846-4